Rain Therapeutics, Inc. Financials

Market Capitalization $25.3 Million as of July 1, 2025

Valuations Metrics as of May. 5, 2024

Trailing PE	-5.00
Forward PE
Price to Sales TTM	C$
Price to Book MRQ	C$-6.81
Enterprise to Revenue
Enterprise to EBITDA	34.10

Financial Reports as of Dec. 31, 2023

Financials

Fiscal Year Ends	2023-09-30
Most Recent Quarter	2023-12-31
Profit Margin	0.00%
Operating Margin	0.00%
Return on Assets TTM	-32.92%
Return on Equity TTM	124.70%

Income Statement

Revenue TTM	C$0
Revenue per Share TTM	C$0.00
Quarterly Revenue Growth	%
Gross Profit TTM	C$0
EBITDA	C$52,099
Net Income to Common TTM	C$-216,196
Diluted EPS TTM	C$-0.01
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	C$95,898
Total Cash per Share MRQ	C$0.00
Total Debt MRQ	C$
Total Debt to Equity MRQ	-0.37
Current Ratio MRQ	0.40
Book Value per Share MRQ	C$-0.01

Cash Flow

Operating Cash Flow TTM	C$-61,566
Levered Free Cash Flow TTM	C$-23,669

RAIN Stock Info as of May. 5, 2024

Stock Statistics

Shares Outstanding	36,031,900
Float Shares	9,330,451
Avg 10 Volume	6,300
Avg 30 Volume	None
Shares Short	372
Short Ratio	4.55
Short % of Shares	%
% Held by Insiders	103.06%
% Held by Institutions	0.00%

Stock Price Summary

Beta	0.63
Fifty Two Week Low	C$0.02
Fifty Two Week High	C$0.09
Fifty Two Week Change	70.00%
Day 50 MA	C$0.03
Day 200 MA	C$0.02

Dividends and Splits

Forward Annual Dividend Rate	C$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	C$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date	2022-05-17